SIGMA GLOBAL LAUNCHES BIOMETIS JOINT VENTURE

Sigma Global, a leading direct-to-consumer provider of medical devices and pharmaceuticals recently announced that it has launched Biometis, a medical device and pharmaceutical joint venture with Stason Pharmaceuticals. Biometis is a Texas corporation with operations in both California and Texas. Biometis intends to introduce its own line of medical devices and generic pharmaceuticals aimed at patients with chronic diseases to retailers, institutions and consumer-direct outlets nationwide. Biometis is limited to new medical devices and generic pharmaceuticals jointly developed by the venture.
Business Wire